---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-034242"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:29:05.255899+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Galectin Therapeutics updates corporate presentation; no new specific data in filing excerpt

## Summary
- Presentation dated September 2025 covers pipeline and strategy, but no clinical or financial figures are disclosed in the filing text.
- Lead candidate belapectin (galectin-3 inhibitor) is highlighted without new trial results or milestones.
- Forward-looking statements caution that actual results may differ materially from projections.
- Investors should review the full presentation on the company's website for material updates.

## SEC filing metadata
- accession: 0001140361-25-034242
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125034242/0001140361-25-034242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125034242/ef20055150_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-034242
- JSON: https://secwatch.observer/filing/0001140361-25-034242.json
- Plain text: https://secwatch.observer/filing/0001140361-25-034242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.